



“ 糖尿病市場首見藥 PS1 開發 ”

Development of the first-in-class diabetes drug, PS1



團隊目前估值為新台幣一億元，預計在執行價創計畫後，估值將達新台幣四億元。


Current pre-money valuation is around NT\$100M. Upon execution of Trust-U project, the post-money valuation is expected to reach NT\$220M.



團隊正尋求 Pre-A 輪募資，預計將募新台幣 1.2 億，以完成 IND 與臨床一期。

We are looking to raise NT\$120M Pre-A round to cover IND application and phase I clinical trials.

產品pipeline



楊文欽 研究員兼副主任 (中央研究院)

Wen-Chin Yang (Academia Sinica)



團隊發現胰島 β 細胞會特定表現伴隨蛋白 PX，可作為糖尿病診斷和治療標的，並研發 PX 小分子抑制劑 PS1。PS1 已證明可透過減少高糖環境下誘導的 ROS，減少 β 細胞死亡和改善 β 細胞功能，在小鼠上達到治療和逆轉糖尿病的功效。

目前已確認 PS1 在動物之最大容忍劑量 (MTD)，為療效劑量的甚多倍，可預見將來臨床一期之不確定性已降低。預計 1 年內將透過價創計畫完成 CMC、毒理試驗並成立公司。預計於 1.5 年內取得 IND 與進入臨床一期，並於 PS1 完成 IND 或臨床一期後對外授權。同時亦將開發 PX 做為糖尿病診斷試劑，為公司創造短期營收，並打造成為台灣診療糖尿病最具代表性之公司。

By discovering the expression of a chaperone protein, PX, in β cells, we concluded that PX protein can be a target for diagnosis, monitoring and treatment of diabetes and then started to develop the small molecule inhibitor PS1. We have proved that PS1 helps improve β cell mass and functions, through reducing high glucose-induced Reactive Oxygen Species (ROS). Mouse models have allowed us a greater appreciation for the effectiveness of PS1 to reverse diabetes and reduce diabetic complications.

It has been confirmed that the Maximum Tolerated Dose (MTD) of PS1 in animals is much more than therapeutic dose so the uncertainty about the future clinical trials are much smaller. In the upcoming year we will complete CMC, toxicology testing and establish a company through Trust-U project. In the next three years, we will submit an IND (Investigational New Drug) application and initiate phase I clinical trials. Before the end of phase II clinical trials, we will proceed to PS1 technology transfer and licensing.

PX can be also developed as a diabetes In Vitro Diagnostic Devices (IVD). It will contribute to revenue of company, making our company one of the most leading companies diagnosing and treating diabetes in Taiwan.